The DOI matches its Crossref record.
Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia
Open accessAbstract
We examined the relationship between the time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia while patients were receiving vancomycin therapy and the in vitro bactericidal activity of vancomycin. Vancomycin killing assays were performed with 34 MRSA bloodstream isolates (17 accessory gene regulator group II [ agr -II] and 17 non- agr -II isolates) from 34 different patients with MRSA bacteremia for whom clinical and microbiological outcomes data were available. Vancomycin doses were prospectively adjusted to achieve peak plasma concentrations of 28 to 32 μg/ml and trough concentrations of 8 to 12 μg/ml. Bactericidal assays were performed over 24 h with ∼10 7 to 10 8 CFU/ml in broth containing 16 μg/ml vancomycin. The median time to clearance of bacteremia was 6.5 days for patients with MRSA isolates demonstrating ≥2.5 reductions in log 10 CFU/ml at 24 h and >10.5 days for patients with MRSA isolates demonstrating <2.5 log 10 CFU/ml by 24 h ( P = 0.025). The median time to clearance was significantly longer with MRSA isolates with vancomycin MICs of 2.0 μg/ml compared to that with MRSA isolates with MICs of ≤1.0 μg/ml ( P = 0.019). The bacteremia caused by MRSA isolates with absent or severely reduced delta-hemolysin expression was of a longer duration of bacteremia (10 days and 6.5 days, respectively; P = 0.27) and had a decreased probability of eradication (44% and 78%, respectively; P = 0.086). We conclude that strain-specific microbiological features of MRSA, such as increased vancomycin MICs and decreased killing by vancomycin, appear to be predictive of prolonged MRSA bacteremia while patients are receiving vancomycin therapy. Prolonged bacteremia and decreased delta-hemolysin expression may also be related. Evaluation of these properties may be useful in the consideration of antimicrobial therapies that can be used as alternatives to vancomycin for the treatment of MRSA bacteremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
“In a more recent study of patients with MRSA bacteremia (n = 34), Moise et al.(58) demonstrated that patients with”
BackgroundHowden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
van Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen
Stryjewski, M. E., & Corey, G. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit613 · Cited by 334
Svetitsky, S., Leibovici, L., & Paul, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-09 · Cited by 275
Increasing Antibiotic Resistance among Methicillin‐Resistant Staphylococcus aureus Strains
Sakoulas, G., & Moellering, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/533592 · Cited by 274
Self-citationClinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Role of Folate Antagonists in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
Goldstein, E. J. C., & Proctor, R. A. (2008) · Clinical Infectious Diseases · doi:10.1086/525536 · Cited by 138
“comycin [33], which is felt to be an important consideration”
BackgroundGasch, O., Camoez, M., Dominguez, M. A., Padilla, B., Pintado, V., Almirante, B., Molina, J., Lopez-Medrano, F., Ruiz, E., Martinez, J. A., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12108 · Cited by 86
Immunomodulatory effects of recombinant lactoferrin during MRSA infection
Hwang, S.-A., Kruzel, M. L., & Actor, J. K. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.029 · Cited by 33
Metadata
- Authors
- Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-07
- Volume
- 51
- Issue
- 7
- Pages
- 2582-2586
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2116331284
- Cited by
- 225
- References
- 0
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.